Therefore, it can be predicted from the mechanism of action that the anti-angiogenic effect of lenvatinib can effectively antagonize the high expression of VEGF after TACE, and the sequential application of the two therapeutic regimens could certainly be a new direction in the treatment exploration for HCC. Here, VEGFA is linked to hepatocellular carcinoma.